A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY
Latest Information Update: 27 Dec 2024
Price :
$35 *
At a glance
- Drugs PF 07976016 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Pfizer
- 24 Dec 2024 Planned End Date changed from 23 Jan 2026 to 17 Jan 2026.
- 24 Dec 2024 Planned primary completion date changed from 19 Dec 2025 to 13 Dec 2025.
- 24 Dec 2024 Status changed from not yet recruiting to recruiting.